Fresh from the disclosure that Strattera may increase suicide risk, the drugs for attention-deficit/ hyperactivity dis-order (ADHD) have now sustained a new series of body blows. In late February, the US Food and Drug Administration (FDA) directed the manufacturers of all ADHD drugs to include special inserts warning patients of cardio-vascular risks and new psychiatric symptoms.
These so-called 'Patient Medica-tion Guides'-handouts given to the patient or his parents by the pharmacist when the drug is prescribed-warn patients of serious 'cardiovascular events' when taking the drug at the usual prescription levels, and attempt to offer FDA-approved advice on how to prevent these problems from happening. Drug manufacturers have been told that they must create the handouts within the next month.
You're a click away from some of the best health information on the web!
If you're already a member please log in
We ask everyone to join the WDDTY site first. It's free to see the News and Community items, but Features and premium content are only available to Digital or Print & Digital Bundle Subscribers. Click here for more information.